Next 10 |
2024-07-17 09:50:00 ET Summary The Fund (Investor Shares) returned -5.80% (net of fees) for the quarter, underperforming the Russell Midcap Index’s -3.35% return. The portfolio’s underperformance was primarily driven by stock selection. The Health Care and Industrial...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 15:00:45 ET More on BioMarin Pharmaceutical, Legend Biotech, etc. Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain Legend Biotech's Carvykti Faces Stiff Challeng...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-27 14:15:02 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Sector Perform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus...
2024-06-27 08:00:12 ET Mohit Bansal from Wells Fargo issued a price target of $115.00 for BMRN on 2024-06-27 06:54:00. The adjusted price target was set to $115.00. At the time of the announcement, BMRN was trading at $85.25. The overall price target consensus is at $110...
2024-06-20 05:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health PR Newswire New Investigator-Led Study Shows VOXZOGO Significan...
2024-06-14 15:00:00 ET More on the markets SPY Is Sub-Optimal For Long-Term Diversified Investors S&P 500 Peaks And VIX Valleys As Market Signals Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) Citi says ETFs will engulf U.S. as...
2024-06-10 07:17:18 ET S&P Dow Jones Indices is set to adjust its mid-cap S&P 400 indices as part of its quarterly rebalancing.... Read the full article on Seeking Alpha For further details see: S&P 400 rejig: HTZ, PENN to exit index; Illumina moves down from S&a...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-27 14:15:02 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Sector Perform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus...